James Bolognese

Statistics

Publications

Citations

564

H-Index

Active since

1999

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

James Bolognese is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, clinical pharmacology, and pharmacotherapy.

Publications per year

1999–2000

Publications

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip

Grant W. Cannon, Jacques R. Caldwell, Peter R. Holt et al. · Arthritis & Rheumatism · 2000 · 279 citations

Medicine, Pharmacology, Pharmacotherapy +15

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Elliot Ehrich, Thomas J. Schnitzer, Harris McIlwain et al. · PubMed · 1999 · 148 citations

Medicine, Pharmacology, Pharmacotherapy +13

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis

Thomas J. Schnitzer, K. E. Truitt, Roy Fleischmann et al. · Clinical Therapeutics · 1999 · 137 citations

Medicine, Pharmacology, Pharmacotherapy +12

1–3 of 3